Odyssey Therapeutics to Participate in Stifel 2026 Virtual Immunology and Inflammation Forum
Odyssey Therapeutics will webcast its September 23, 2026 presentation at the Stifel Virtual Immunology and Inflammation Forum for live and replay viewing.
Rhea-AI Summary
Odyssey Therapeutics (ODTX)/b) will present at the Stifel 2026 Virtual Immunology and Inflammation Forum on Wednesday, September 23 at 11:00 AM ET. The clinical-stage biopharmaceutical company focuses on developing medicines that precisely target disease pathology in autoimmune and inflammatory diseases. A live webcast of the presentation will be accessible on the day of the event under the
Positive
- None.
Negative
- None.
Details
Market reaction after immunology forum presentation: ODTX +5.23%
Following this news, ODTX has gained 5.23%, reflecting a notable positive market reaction. Our momentum scanner has triggered 7 alerts so far, indicating moderate trading interest and price volatility. The stock is currently trading at $23.14.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
- Presentation time
- September 23 at 11:00 AM ET
- Stifel 2026 Virtual Immunology and Inflammation Forum
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Odyssey Therapeutics, Inc. (Nasdaq: ODTX) (“Odyssey” or the “Company”), a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by developing medicines that precisely target disease pathology, today announced that members of its management team are scheduled to present at the Stifel 2026 Virtual Immunology and Inflammation Forum on Wednesday, September 23 at 11:00 AM ET.
A live webcast will be available under “News and Events” in the Investors section of the Company’s website at www.odysseytx.com on the day of the event. A replay of the webcast will be available on the Events page of Odyssey’s investor website and archived for 60 days.
About Odyssey Therapeutics
Odyssey Therapeutics is a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by developing medicines that are designed to precisely target disease pathology. Since its founding in 2021, Odyssey has built a portfolio of internally discovered and developed medicines with its first program advancing through multiple clinical milestones. Odyssey’s portfolio leverages the scientific expertise of its team of experienced drug hunters and a comprehensive suite of tools to efficiently advance product candidates that the Company believes have the potential to induce deep and durable remission for patients across several inflammatory diseases with unmet need.
For more information, please visit https://odysseytx.com/ and follow Odyssey on LinkedIn or X.
Contacts
Investor Relations
Collin Todd
SVP, Strategy and Business Development
investors@odysseytx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
When and at what time will Odyssey Therapeutics present at the forum?
The company’s management team is scheduled to present at the Stifel 2026 Virtual Immunology and Inflammation Forum on Wednesday, September 23 at 11:00 AM ET.
How can investors access the live webcast of Odyssey’s presentation?
A live webcast will be available on the day of the event under “News and Events” in the Investors section of the company’s website at www.odysseytx.com.
Will a replay of the presentation be available after the event?
Yes. A replay of the webcast will be available on the Events page of Odyssey’s investor website and will be archived for 60 days.
What therapeutic focus does Odyssey Therapeutics highlight in this announcement?
Odyssey describes itself as a clinical-stage biopharmaceutical company developing medicines that precisely target disease pathology for patients with autoimmune and inflammatory diseases.